Results 121 to 130 of about 530,731 (290)

A novel single-vector featuring bidirectional promoters for production of bispecific antibody against rabies virus

BMC Biotechnology
Background The World Health Organization (WHO) recommends combination therapy with two non-overlapping monoclonal antibodies (mAbs) to enhance protection in Rabies post-exposure prophylaxis (PEP).
Zhigao Zhang, Jia Li, Guanfeng Lin, Shouchun Cao, Yingsong Wu   +4 more
doaj   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

Brain distribution of a bispecific antibody targeting Aβ [Elektronisk resurs]

, 2022
Alzheimer’s disease (AD) is characterised by aberrant protein aggregation in the brain with subsequent synaptic loss, neuroinflammation, and brain atrophy that ultimately clinically manifests as cognitive impairment.
Syvänen, Stina,, Stanimirovic, Danica,, Sehlin, Dag,, Tobias, Gustavsson,, O'Callaghan, Paul,   +4 more
core  

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Bispecific antibodies targeting human CD73

, 2017
The present invention relates to a bispecific antibody targeting CD73. In particular, the present invention relates to a bispecific antibody targeting different epitopes on CD73 or a bispecific antibody targeting an epitope on CD73 and an epitope on a ...
Gammelgaard, Odd Lilleng, Ditzel, Henrik
core   +1 more source

Data_Sheet_1_Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells.PDF

, 2019
Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although, there are effective treatments not every patient responds, necessitating the development of novel therapeutic approaches, especially for relapsed and refractory cases ...
Yating Li (1819822), Evelyn Ngoh (7420457), Hiu Yi Wong (6881579), Sakthi Rajendran (7420454), Cheng-I Wang (123226), Man Si Cheng (7420460), Herbert Schwarz (357714)   +6 more
core   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source

A Rare Case of Acquired Haemophilia A Following Sigmoid Adenocarcinoma: Case Report and Literature Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Acquired haemophilia A (AHA) is a rare complication of malignancy. We report a case of AHA secondary to colorectal cancer which presented as post‐operative bleeding, progressive activated partial thromboplastin time prolongation, precipitous factor VIII (FVIII) decline and inhibitor development.
Benjamin Reardon, Harini Haran, Jennifer Curnow   +2 more
wiley   +1 more source